专利: US11236144B2/CN105431449B
简介
PD-1异构体是免疫检查点PD-1分子的独特异构体。与野生型PD-1分子的免疫调节功能不同，PD-1异构体能够促进炎症反应。
PD-1 异构体抑制平台能有效减低炎症反应
抗Δ42PD1阻断抗体平台
我们的抗PD-1异构体抗体专利平台能有效阻止PD-1异构体与其关联受体的相互作用，从而达到减低炎症反应的效果，继而降低炎症引发的病理异常。
PD-1异构体抑制平台在肿瘤抑制中的作用
PD-1异构体诱导的炎症反应可导致T细胞衰竭和功能丧失，令到肿瘤细胞不能被清除。我们正在评估此抗体平台对逆转T细胞衰竭来治疗癌症的潜在治疗效果。
参考文献：
Cheng L, Tang X, Liu L, Peng J, Nishiura K, Cheung AKL, et al. Monoclonal antibodies specific to human Δ42PD1: A novel immunoregulator potentially involved in HIV-1 and tumor pathogenesis. mAbs. 2015 Feb 18;7(3):620–9. Available from: https://doi.org/10.1080/19420862.2015.1016695
Cheung AKL, Kwok HY, Huang Y, Chen M, Mo Y, Wu X, et al. Gut-homing Δ42PD1+Vδ2 T cells promote innate mucosal damage via TLR4 during acute HIV type 1 infection. Nature Microbiology. 2017 Aug 14;2(10):1389–402. Available from: https://doi.org/10.1038/s41564-017-0006-5
Liu L, Fang J, Gong R, Peng J, Cao T, Peng Q, et al. Isoformic PD-1 impedes B cell activation and function in HIV-1 infection. Cell Reports. 2025 Oct 1;44(10):116341. Available from: https://doi.org/10.1016/j.celrep.2025.116341
Tan Z, Chiu MS, Yang X, Yue M, Cheung TT, Zhou D, et al. Isoformic PD-1-mediated immunosuppression underlies resistance to PD-1 blockade in hepatocellular carcinoma patients. Gut. 2022 Nov 30;72(8):1568–80. Available from: https://doi.org/10.1136/gutjnl-2022-327133
